Dyslipidaemia as a target for atherosclerotic cardiovascular disease prevention in children with type 1 diabetes: lessons learned from familial hypercholesterolaemia

Abstract

In the last few decades, atherosclerotic cardiovascular disease (ASCVD) risk has decreased dramatically among individuals affected by familial hypercholesterolaemia (FH) as a result of the early initiation of statin treatment in childhood. Contemporaneously important improvements in care for people with diabetes have also been made, such as the prevention of mortality from acute diabetic complications. However, individuals with type 1 diabetes still have a two to eight times higher risk of death than the general population. In the last 20 years, a few landmark studies on excess mortality in people with type 1 diabetes, in particular young adults, have been published. Although these studies were carried out in different populations, all reached the same conclusion: individuals with type 1 diabetes have a pronounced increased risk of ASCVD. In this review, we address the role of lipid abnormalities in the development of ASCVD in type 1 diabetes and FH. Although type 1 diabetes and FH are different diseases, lessons could be learned from the early initiation of statins in children with FH, which may provide a rationale for more stringent control of dyslipidaemia in children with type 1 diabetes. Graphical Abstract

Care, control and complications of hospitalised patients with type 1 diabetes in China: A nationwide‐based registry study

“…A disease duration of more than 10 years, eastern regions, or high-GDP regions were associated with a higher achievement rate of glycated haemoglobin. Dyslipidemia, as a target for atherosclerotic cardiovascular disease prevention, 32 is still a common concomitant disease of T1D, which is related to glucose control.…”

Investigating the Incidence of Dyslipidemia among Brazilian Children and Adolescents Diagnosed with Type 1 Diabetes Mellitus: A Cross-Sectional Study

“…However, there is growing concern about changes in the concentrations of the apolipoproteins (Apo)B and ApoA-I in children and adolescents with T1DM. Monitoring these apolipoproteins is mainly useful in monitoring cardiovascular risk of T1DM patients who have low-density lipoprotein cholesterol-(LDL-c) and high-level lipoprotein-cholesterol (HDL-c) values within the normal range [ 23 , 24 ].…”